Verastem | TalkMarkets

Latest Posts

Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal

Article By: ChinaBio® Today

Saturday, September 2, 2023 1:59 PM EDT

Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet will receive an initial payment of $11.5 million.

In this article: VSTM Also: BNTX, IMAB

Read

Where Is VSTM Headed?

Article By: Zion Miller

Tuesday, January 22, 2019 11:17 PM EDT

With the recent bashing of the market as a whole and slaughter of small caps, VSTM continues to touch what some claim to be unfathomable levels.

In this article: VSTM Also: GILD, BMY, JNJ, MRK, NVS, RHHBY

Read

Verastem, De Risked?

Article By: Zion Miller

Monday, December 31, 2018 4:11 PM EDT

VSTM has been pushed down for several reasons and was further damaged with the recent unfortunate bearish markets.

In this article: VSTM

Read

Week In Review: Agilent Pays $250 Million To Acquire ACEA And Its Cell Therapy Analyzer

Article By: ChinaBio® Today

Saturday, September 29, 2018 4:11 PM EDT

ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhzou, will be acquired by Agilent for $250 million in cash. ACEA developed the xCELLigence® cell therapy analysis device used by academic and biopharma researchers.

In this article: A, VSTM, NVS, CBMG, TTPH

Read